Etorphine is available legally only for
veterinary use and is strictly governed by law. It is often used to immobilise
elephants and other large mammals.
Diprenorphine (Revivon) is an opioid receptor antagonist that can be administered in proportion to the amount of etorphine used (1.3 times) to reverse its effects. Veterinary-strength etorphine is fatal to humans. For this reason the package as supplied to vets always includes the human antidote along with the etorphine. The human antidote is generally
naloxone, not diprenorphine, and is always prepared before the preparation of etorphine to be immediately administered following accidental human exposure to etorphine. The in humans is 3 μg which led to the requirement that the medicine include an equivalent dose of an antidote. One of its main advantages is its speed of operation, and more importantly, the speed that
diprenorphine reverses its effects. The high incidence of side effects, including severe cardiopulmonary depression, has caused etorphine to fall into disfavor in general veterinary practice. However, its high potency, combined with the rapid action of both etorphine and its antagonist, diprenorphine, means that it has found a place for use in the capture of large mammals, such as rhinoceroses and elephants, where rapid onset and rapid recovery are both very important. The high potency of etorphine means that sufficient etorphine can be administered to large wild mammals by projectile syringe (dart).
Large Animal Immobilon is a combination of etorphine plus
acepromazine maleate. An etorphine antidote
Large Animal Revivon contains mainly diprenorphine for animals and a human-specific
naloxone-based antidote, which should be prepared prior to the etorphine. A 5–15 mg dose is enough to immobilise an
African elephant and a 2–4 mg dose is enough to immobilise a
black rhinoceros. == Pharmacology ==